PapersFlow Research Brief
Neuroblastoma Research and Treatments
Research Guide
What is Neuroblastoma Research and Treatments?
Neuroblastoma Research and Treatments is a field of medical research focused on the genetic mutations such as ALK and MYCN, risk classification, staging systems, immunotherapy, genomic analysis, therapy strategies, and prognosis for neuroblastoma, a pediatric cancer originating from neural crest cells.
Neuroblastoma research encompasses 51,369 published works examining genetic mutations including ALK and MYCN, risk classification, staging systems, immunotherapy, and genomic analysis. Studies address therapy strategies and prognosis for patients with this neural crest-derived tumor. Growth rate over the past five years is not available in the provided data.
Topic Hierarchy
Research Sub-Topics
MYCN Amplification in Neuroblastoma
Researchers study the role of MYCN oncogene amplification as a key prognostic marker and driver of aggressive neuroblastoma tumors. Genomic profiling and functional studies explore targeted therapies against MYCN-driven pathways.
ALK Mutations in Neuroblastoma
This sub-topic investigates activating ALK kinase mutations, their prevalence, and response to ALK inhibitors like lorlatinib in relapsed neuroblastoma. Clinical trials and preclinical models assess mutation-specific treatments.
Neuroblastoma Risk Classification Systems
Studies refine INSS, INRGSS, and molecular-based systems integrating age, stage, histology, and genetics for prognosis prediction. Researchers validate and update classifications using large cohorts.
Immunotherapy for Neuroblastoma
Research focuses on GD2-targeted monoclonal antibodies, CAR-T cells, and checkpoint inhibitors to overcome neuroblastoma's immune evasion. Phase I-III trials evaluate combination regimens and biomarkers.
Neuroblastoma Genomic Profiling
This area covers whole-genome sequencing, hyperdiploidy, and segmental chromosome aberrations to uncover heterogeneity and new targets. Integrative analyses link genomics to clinical features.
Why It Matters
Neuroblastoma research impacts pediatric oncology by informing risk classification and staging systems that guide therapy selection and prognosis prediction. Louis et al. (2021) in "The 2021 WHO Classification of Tumors of the Central Nervous System: a summary" updated standards for classifying CNS tumors, including embryonal tumors like neuroblastoma, enabling precise diagnosis and treatment planning. Similarly, Louis et al. (2007) in "The 2007 WHO Classification of Tumours of the Central Nervous System" established prior frameworks that support genomic analysis and immunotherapy approaches. These classifications have facilitated advances in managing high-risk cases through targeted therapies against mutations such as MYCN amplification.
Reading Guide
Where to Start
"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary" by Louis et al. (2021), as it provides the most recent summary of CNS tumor classifications relevant to neuroblastoma diagnosis and staging.
Key Papers Explained
Louis et al. (2021) in "The 2021 WHO Classification of Tumors of the Central Nervous System: a summary" builds on Louis et al. (2007) in "The 2007 WHO Classification of Tumours of the Central Nervous System" by incorporating molecular advances for embryonal tumors like neuroblastoma. The 2007 erratum by Louis et al. (2007) corrects the foundational classification. Brahmer et al. (2018) in "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy" complements these by addressing immunotherapy safety applicable to neuroblastoma protocols.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to emphasize ALK and MYCN mutations, risk classification, and immunotherapy per the topic description. No recent preprints or news from the last 12 months are available. Genomic analysis and prognosis studies represent ongoing priorities.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Human Breast Cancer: Correlation of Relapse and Survival with ... | 1987 | Science | 11.6K | ✕ |
| 2 | The 2021 WHO Classification of Tumors of the Central Nervous S... | 2021 | Neuro-Oncology | 10.6K | ✓ |
| 3 | Guía de práctica clínica para el tratamiento de los tumores in... | 2009 | — | 5.3K | ✕ |
| 4 | The 2007 WHO Classification of Tumours of the Central Nervous ... | 2007 | Acta Neuropathologica | 4.6K | ✓ |
| 5 | One Hundred Years After “Carcinoid”: Epidemiology of and Progn... | 2008 | Journal of Clinical On... | 4.5K | ✕ |
| 6 | Erratum to: The 2007 WHO classification of tumours of the cent... | 2007 | Zurich Open Repository... | 4.5K | ✓ |
| 7 | THE METABOLISM OF TUMORS IN THE BODY | 1927 | The Journal of General... | 4.2K | ✓ |
| 8 | Management of Immune-Related Adverse Events in Patients Treate... | 2018 | Journal of Clinical On... | 3.5K | ✓ |
| 9 | Pathology of Tumours of the Nervous System | 1990 | Journal of Neuropathol... | 3.5K | ✕ |
| 10 | Trends in the Incidence, Prevalence, and Survival Outcomes in ... | 2017 | JAMA Oncology | 3.4K | ✓ |
Frequently Asked Questions
What genetic mutations are central to neuroblastoma research?
ALK and MYCN mutations are key genetic alterations studied in neuroblastoma. These mutations drive tumor progression and inform risk classification. Genomic analysis targets them for prognosis and therapy development.
How do WHO classifications contribute to neuroblastoma treatment?
The 2021 WHO Classification by Louis et al. summarizes updates for CNS tumors, including neuroblastoma features for accurate staging. The 2007 version by Louis et al. provides foundational criteria for neuroepithelial tumors. Both aid in selecting immunotherapy and other therapies.
What role does immunotherapy play in neuroblastoma?
Immunotherapy is a focus in neuroblastoma research alongside genetic mutations and risk stratification. Brahmer et al. (2018) in "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy" outline guidelines for handling adverse events from such therapies. These strategies support safe application in pediatric cases.
What is the scope of neuroblastoma staging systems?
Staging systems in neuroblastoma research integrate genomic data, risk classification, and tumor biology. WHO classifications like Louis et al. (2021) standardize assessment for prognosis. They enable tailored therapy strategies based on mutation profiles.
How many papers exist on neuroblastoma research?
There are 51,369 works on neuroblastoma research and treatments. These cover genetic mutations, immunotherapy, and prognosis. No five-year growth rate is specified in the data.
Open Research Questions
- ? How can ALK and MYCN mutation profiles improve risk stratification beyond current WHO classifications?
- ? What genomic markers predict immunotherapy response in high-risk neuroblastoma?
- ? Which staging system revisions would best integrate new data on neuroblastoma prognosis?
- ? How do therapy strategies targeting neural crest origins enhance survival in metastatic cases?
Recent Trends
Neuroblastoma research includes 51,369 papers with no specified five-year growth rate.
Keywords highlight persistent focus on ALK, MYCN, genomic analysis, immunotherapy, and risk classification.
Louis et al. reflects the latest WHO update on CNS tumors, but no preprints or news from the last 12 months indicate current developments.
2021Research Neuroblastoma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroblastoma Research and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers